Faeth Therapeutics, Inc. (FTH)
FTHNASDAQ-CMBiotechnology: Pharmaceutical Preparations
$12.78
+0.1013 (+0.80%) today
At the close, Nov 10, 4:00 PM ET. After hours $12.60 -2.48%
- Market cap
- $333.90m
- P/E
- –
- EPS, last 4 quarters
- $-138.82
- Dividend yield
- –
- Day range
- $11.83 to $13.93
- 52-week range
- $7.45 to $42.14
- Average volume
- 457.9k
- Previous close
- $12.68
Analysts
10 coveringBuy10 buy, 0 hold, 0 sell
Targets a year out average $57.78, +352.1% from here
Earnings
next estimate $-0.7000Next report
Dec 2025
–
Mar 2026
–
Jun 2026
-158.2%
Sep 2026
-19.7%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$4.96m | -$170.63m | -$18.39m | -$22.09m |
| Net income | -$4.72m | -$170.24m | -$16.01m | -$20.40m |
News
8 latest- Sensei Biotherapeutics Announces Phase 2 PIK-201 Topline Results for PIKTOR in Endometrial CancerFintel · 1 day ago
- Sensei Biotherapeutics, Inc. Reports Positive Preliminary Phase 2 Topline Results from the PIK-201 TrialFintel · 1 day ago
- Sensei Biotherapeutics, Inc. Reports Third Quarter 2026 Financial ResultsFintel · Nov 3, 2026
- Sensei Biotherapeutics, Inc. Appoints Adam Schayowitz to Board of Directors on October 23, 2026Fintel · Oct 27, 2026
- Sensei Biotherapeutics Highlights PIKTOR Strategy Ahead of Endometrial Trial ReadoutMarketBeat · Oct 7, 2026
- Lucid Capital Markets Initiates Coverage of Faeth Therapeutics with BuyFintel · Sep 14, 2026
- Biotech Stocks At 52-Week Highs - PHVS +7%, ROIV +6% On Trial Readouts, BLSM +4%, ATRC, FTH RTTNews · Sep 9, 2026
- Biotech Stocks At 52-Week Highs - OABI +13%, FRNM, EXEL, FTH, LFST RTTNews · Sep 3, 2026
The company
Faeth Therapeutics, Inc. (Nasdaq: FTH) is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The Company's lead program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer. Faeth was co-founded in 2019 by Anand Parikh and Oliver Maddocks, Ph.D., together with scientific founders Lewis Cantley, Ph.D., the discoverer of the PI3K pathway; Siddhartha Mukherjee, M.D., D.Phil.; Karen Vousden, Ph.D.; Scott Lowe, Ph.D.; and Greg Hannon, Ph.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- senseibio.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.